1. Combined Electric acoustic stimulation in a patient with otitis media with antineutrophil cytoplasmic antibody-associated vasculitis
- Author
-
Takumi Okuda, Yuusuke Yamada, Shoken Shimoara, Yusuke Matsuda, Takeshi Nakamura, Akira Ganaha, and Tetsuya Tono
- Subjects
Electric acoustic stimulation ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Magnetic resonance imaging ,General Medicine ,medicine.disease ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,Otitis ,Otorhinolaryngology ,030220 oncology & carcinogenesis ,Cochlear implant ,otorhinolaryngologic diseases ,medicine ,medicine.symptom ,030223 otorhinolaryngology ,Cochlear implantation ,Vasculitis ,business ,Speech discrimination score ,Anti-neutrophil cytoplasmic antibody - Abstract
There are few reports of the treatment for severe hearing loss due to otitis media with antineutrophil cytoplasmic antibody-associated vasculitis (OMAAV) achieved by cochlear implantation (CI). Here, we have reported the case of a patient with severe bilateral sensorineural hearing loss with low-frequency residual hearing by OMAAV. CI was performed in her right ear based on the results of contrast-enhanced magnetic resonance imaging (CE-MRI) and promontory stimulation test (PST). The residual hearing in her right ear was preserved after CI and utilized for combined electric acoustic stimulation (EAS). The combined EAS was used for 3 years until the residual hearing became stabilized. However, the usable hearing in low frequency worsened gradually, and the fitting strategy of cochlear implant was changed from combined EAS to CI alone 4 years after CI. Even when the speech discrimination score with CI no longer exceeds 50 %, the patient continued using CI because of its advantages in maintaining the quality of life of the patient. The combined EAS was found to be a feasible option even in an OMAAV patient with residual hearing. CE-MRI and PST may thus be helpful in deciding the side of CI surgery in a patient with OMAAV.
- Published
- 2022